Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, operates in the industry of developing treatments for rare diseases. The company is specifically focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum Therapeutics has developed a proprietary product engine, FulcrumSeek, which is used to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined diseases. The...
| S.No. | Ticker | Company | Market Cap | P/E | P/S | Total Debt (Qtr) |
|---|---|---|---|---|---|---|
| 1 | VRTX | Vertex Pharmaceuticals Inc / Ma | 113.30 Bn | 28.64 | 9.44 | - |
| 2 | REGN | Regeneron Pharmaceuticals, Inc. | 78.40 Bn | 17.37 | 5.47 | 1.99 Bn |
| 3 | ALNY | Alnylam Pharmaceuticals, Inc. | 41.41 Bn | 150.53 | 13.15 | - |
| 4 | MESO | Mesoblast Ltd | 21.68 Bn | -169.86 | 1,260.73 | 0.12 Bn |
| 5 | RPRX | Royalty Pharma plc | 19.93 Bn | 25.90 | 8.38 | 8.95 Bn |
| 6 | ZLAB | Zai Lab Ltd | 19.57 Bn | -111.69 | 80.73 | 0.20 Bn |
| 7 | MRNA | Moderna, Inc. | 18.75 Bn | -6.63 | 9.65 | 0.59 Bn |
| 8 | ROIV | Roivant Sciences Ltd. | 18.40 Bn | -30.01 | 3,205.68 | - |